Koers Hemispherx BioPharma, Inc Nyse
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 113K 105K | Omzet 2025 * | 1,78 mln. 1,65 mln. | Marktkapitalisatie | 21,79 mln. 20,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -24 mln. -22,26 mln. | Nettowinst (verlies) 2025 * | -25 mln. -23,19 mln. | EV/omzet 2024 * | 192 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 12,2 x |
K/w-verhouding 2024 * |
-0,89
x | K/w-verhouding 2025 * |
-0,96
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91% |
Recentste transcriptie over Hemispherx BioPharma, Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 17-11-08 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 04-04-22 |
Chief Tech/Sci/R&D Officer | - | 01-06-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 28-03-23 |
William Mitchell
CHM | Chairman | 89 | 01-07-98 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 17-11-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,97% | 108 mld. | |
+10,21% | 104 mld. | |
+2,85% | 22,33 mld. | |
-12,77% | 22,19 mld. | |
-7,05% | 18,69 mld. | |
-37,64% | 17,74 mld. | |
-6,50% | 17,64 mld. | |
+6,00% | 14,05 mld. | |
+37,20% | 12,51 mld. |